Scientific advances in lung cancer 2015

Journal of Thoracic Oncology

Volumn 11, Issue 5, 2016, Pages 613-638

  Tsao, Anne S ^a   Scagliotti, Giorgio V ^b   Bunn, Paul A ^c   Carbone, David P ^d   Warren, Graham W ^e   Bai, Chunxue ^f   De Koning, Harry J ^g   Uraujh Yousaf Khan, A ^g   McWilliams, Annette ^h   Tsao, Ming Sound ⁱ   Adusumilli, Prasad S ^j   Rami Porta, Ramón ^k,l   Asamura, Hisao ^m   Van Schil, Paul E ⁿ   Darling, Gail E ^o   Ramalingam, Suresh S ^p   Gomez, Daniel R ^a   Rosenzweig, Kenneth E ^q   Zimmermann, Stefan ^r   Peters, Solange ^s   Ou, Sai Hong Ignatius ^t   Reungwetwattana, Thanyanan ^u   Jänne, Pasi A ^v   Mok, Tony S ^w   Wakelee, Heather A ^x   Pirker, Robert ^y   Mazières, Julien ^z   Brahmer, Julie R ^aa   Zhou, Yang ^ab   Herbst, Roy S ^ab   Papadimitrakopoulou, Vassiliki A ^a   Redman, Mary W ^ac   Wynes, Murry W ^ad   Gandara, David R ^ae   Kelly, Ronan J ^aa   Hirsch, Fred R ^c   Pass, Harvey I ^af   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f FUDAN UNIVERSITY   (China)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h FIONA STANLEY HOSPITAL   (Australia)

ⁱ PRINCESS MARGARET HOSPITAL   (Canada)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^l INSTITUTO DE SALUD CARLOS III   (Spain)

^m KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^o UNIVERSITY OF TORONTO   (Canada)

^p EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^r University of Lausanne ^*  (Switzerland)

^s UNIVERSITY OF LAUSANNE   (Switzerland)

^t UNIVERSITY OF CALIFORNIA   (United States)

^u MAHIDOL UNIVERSITY   (Thailand)

^v HARVARD MEDICAL SCHOOL   (United States)

^w CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^x STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^y MEDICAL UNIVERSITY OF VIENNA   (Austria)

^z UNIVERSITÉ PAUL SABATIER   (France)

^aa JOHNS HOPKINS UNIVERSITY   (United States)

^ab YALE CANCER CENTER   (United States)

^ac USA   (United States)

^ad International Association for the Study of Lung Cancer   (United States)

^ae UNIVERSITY OF CALIFORNIA   (United States)

^af NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Adjuvant chemotherapy; Biomarkers; Cancer prevention; Gene mutations; Immunotherapy; Lung cancer; Master protocols; Pathology; Radiotherapy; Screening; Smoking cessation; Staging; Surgery; Targeted therapy; Value of therapy

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; K RAS PROTEIN; NERVE GROWTH FACTOR RECEPTOR; PROTEIN RET; SCATTER FACTOR RECEPTOR;

ADVANCED CANCER; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; GENE REARRANGEMENT; HEALTH SURVEY; HUMAN; LUNG CANCER; LUNG NODULE; NON SMALL CELL LUNG CANCER; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SMALL CELL LUNG CANCER; SMOKING CESSATION; TOBACCO CONSUMPTION; IMMUNOTHERAPY; LUNG TUMOR; PERSONALIZED MEDICINE;

HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; PRECISION MEDICINE; QUALITY OF LIFE;

EID: 84969833490     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.03.012     Document Type: Review

References (256)

1. Bunn PA Jr, Minna J, Augustyn A, et al. Small cell lung cancer: can recent advances in biology and molecular biology be translated into improved outcomes? J Thorac Oncol. 2016;11:453-474.
2. U.S. Department of Health and Human Services. The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services; 2014.
3. Hackshaw AK. Lung cancer and passive smoking. Stat Methods Med Res. 1998;7:119-136.
4. Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med. 2013;368:351-364.
5. Chen ZM, Peto R, Iona A, et al. Emerging tobacco-related cancer risks in China: a nationwide, prospective study of 0.5 million adults. Cancer. 2015;121(suppl 17):3097-3106.
6. Warren GW, Sobus S, Gritz ER. The biological and clinical effects of smoking by patients with cancer and strategies to implement evidence-based tobacco cessation support. Lancet Oncol. 2014;15:e568-e580.
7. Dobson Amato KA, Hyland A, Reed R, et al. Tobacco cessation may improve lung cancer patient survival. J Thorac Oncol. 2015;10:1014-1019.
8. Leone FT, Carlsen KH, Folan P, et al. An official American Thoracic Society Research statement: current understanding and future research needs in tobacco control and treatment. Am J Respir Crit Care Med. 2015;192:e22-e41.
9. World Lung Foundation-American Cancer Society. The tobacco atlas. http://www.tobaccoatlas.org/. Accessed January 22, 2016.
10. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395-409.
11. Tanner NT, Kanodra NM, Gebregziabher M, et al. The association between smoking abstinence and mortality in the National Lung Screening Trial. Am J Respir Crit Care Med. 2016;193:534-541.
12. Warren GW, Dibaj S, Hutson A, et al. Identifying targeted strategies to improve smoking cessation support for cancer patients. J Thorac Oncol. 2015;10:1532-1537.
13. Warren GW, Ward KD. Integration of tobacco cessation services into multidisciplinary lung cancer care: rationale, state of the art, and future directions. Transl Lung Cancer Res. 2015;4:339-352.
14. Moyer VA. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160:330-338.
15. Saghir Z, Dirksen A, Ashraf H, et al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. Thorax. 2012;67:296-301.
16. Infante M, Cavuto S, Lutman FR, et al. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am J Respir Crit Care Med. 2009;180:445-453.
17. Pastorino U, Rossi M, Rosato V, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev. 2012;21:308-315.
18. van Klaveren RJ, Oudkerk M, Prokop M, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med. 2009;361:2221-2229.
19. van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer. 2007;120:868-874.
20. Xu DM, Gietema H, de Koning H, et al. Nodule management protocol of the NELSON randomised lung cancer screening trial. Lung Cancer. 2006;54:177-184.
21. Ru Zhao Y, Xie X, de Koning HJ, et al. NELSON lung cancer screening study. Cancer Imaging. 2011, 11 Spec No A:S79-S84.
22. Horeweg N, van der Aalst CM, Vliegenthart R, et al. Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial. Eur Respir J. 2013;42:1659-1667.
23. Aberle DR, Berg CD, Black WC, et al. The National Lung Screening Trial: overview and study design. Radiology. 2011;258:243-253.
24. Tammemagi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. N Engl J Med. 2013;368:728-736.
25. Kovalchik SA, Tammemagi M, Berg CD, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med. 2013;369:245-254.
26. Tammemagi MC, Lam S. Screening for lung cancer using low dose computed tomography. BMJ. 2014;348:g2253.
27. Field JK, Smith RA, Aberle DR, et al. International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report. J Thorac Oncol. 2012;7:10-19.
28. Tammemagi MC. Application of risk prediction models to lung cancer screening: a review. J Thorac Imaging. 2015;30:88-100.
29. Tammemagi CM, Pinsky PF, Caporaso NE, et al. Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation. J Natl Cancer Inst. 2011;103:1058-1068.
30. Tammemagi MC, Church TR, Hocking WG, et al. Evaluation of the lung cancer risks at which to screen ever-and never-smokers: screening rules applied to the PLCO and NLST cohorts. PLoS Med. 2014;11:e1001764.
31. Hoggart C, Brennan P, Tjonneland A, et al. A risk model for lung cancer incidence. Cancer Prev Res (Phila). 2012;5:834-846.
32. Cressman S, Lam S, Tammemagi MC, et al. Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada. J Thorac Oncol. 2014;9:1449-1458.
33. Cressman S, Lam S, Tammemägi M, et al. Economic Evidence for the Use of Risk-Selection and Risk-Stratification for Lung Cancer Screening Programs. J Thorac Oncol. 2015;10:S192.
34. Black WC, Gareen IF, Soneji SS, et al. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med. 2014;371:1793-1802.
35. McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med. 2013;369:910-919.
36. Winkler Wille MM, van Riel SJ, Saghir Z, et al. Predictive accuracy of the PanCan lung cancer risk prediction model-external validation based on CT from the Danish Lung Cancer Screening Trial. Eur Radiol. 2015;25:3093-3099.
37. Al-Ameri A, Malhotra P, Thygesen H, et al. Risk of malignancy in pulmonary nodules: a validation study of four prediction models. Lung Cancer. 2015;89:27-30.
38. Van Riel SJ, Ciompi F, Wille MW, et al. Lung-RADS versus the McWilliams Nodule Malignancy Score for Risk Prediction: Eevaluation on the Danish Lung Cancer Screening Trial. J Thorac Oncol. 2015;10:S191.
39. American College of Radiology. Lung CT Screening Reporting and Data System (Lung-RADS). www.acr.org/Quality-Safety/Resources/LungRADS. Accessed January 17, 2016.
40. Callister ME, Baldwin DR, Akram AR, et al. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax. 2015;70(suppl 2):ii1-ii54.
41. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, eds. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed. Lyon, France: IARC Press; 2015.
42. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of Lung Tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243-1260.
43. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adeno-carcinoma. J Thorac Oncol. 2011;6:244-285.
44. Cha MJ, Lee HY, Lee KS, et al. Micropapillary and solid subtypes of invasive lung adenocarcinoma: clinical predictors of histopathology and outcome. J Thorac Cardiovasc Surg. 2014;147:921-928 e922.
45. Gu J, Lu C, Guo J, et al. Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients - A single institution retrospective study of 292 lung adeno-carcinoma. J Surg Oncol. 2013;107:474-480.
46. Hung JJ, Jeng WJ, Chou TY, et al. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma. Ann Surg. 2013;258:1079-1086.
47. Hung JJ, Yeh YC, Jeng WJ, et al. Predictive value of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification of Lung Adenocarcinoma in tumor recurrence and patient survival. J Clin Oncol. 2014;32:2357-2364.
48. Kadota K, Villena-Vargas J, Yoshizawa A, et al. Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. Am J Surg Pathol. 2014;38:448-460.
49. Russell PA, Wainer Z, Wright GM, et al. Does lung adenocarcinoma subtype predict patient survival? A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol. 2011;6:1496-1504.
50. Song Z, Zhu H, Guo Z, et al. Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocar-cinoma patients-based on a hospital study in China. Eur J Surg Oncol. 2013;39:1262-1268.
51. Tsao MS, Marguet S, Le Teuff G, et al. Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection. J Clin Oncol. 2015;33:3439-3446.
52. Tsuta K, Kawago M, Inoue E, et al. The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. Lung Cancer. 2013;81:371-376.
53. Ujiie H, Kadota K, Chaft JE, et al. Solid predominant histologic subtype in resected stage I lung adenocarci-noma is an independent predictor of early, extra-thoracic, multisite recurrence and of poor postrecurrence survival. J Clin Oncol. 2015;33:2877-2884.
54. Warth A, Muley T, Meister M, et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol. 2012;30:1438-1446.
55. Westaway DD, Toon CW, Farzin M, et al. The International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society grading system has limited prognostic significance in advanced resected pulmonary adenocarcinoma. Pathology. 2013;45:553-558.
56. Woo T, Okudela K, Mitsui H, et al. Prognostic value of the IASLC/ATS/ERS classification of lung adenocarci-noma in stage I disease of Japanese cases. Pathol Int. 2012;62:785-791.
57. Yanagawa N, Shiono S, Abiko M, et al. The correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/Euro-pean Respiratory Society (ERS) classification with prognosis and EGFR mutation in lung adenocarcinoma. Ann Thorac Surg. 2014;98:453-458.
58. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarci-noma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011;24:653-664.
59. Yoshizawa A, Sumiyoshi S, Sonobe M, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol. 2013;8:52-61.
60. Zhang J, Wu J, Tan Q, et al. Why do pathological stage IA lung adenocarcinomas vary from prognosis? a clini-copathologic study of 176 patients with pathological stage IA lung adenocarcinoma based on the IASLC/ATS/ERS classification. J Thorac Oncol. 2013;8:1196-1202.
61. Zhang Y, Li J, Wang R, et al. The prognostic and predictive value of solid subtype in invasive lung adeno-carcinoma. Sci Rep. 2014;4:7163.
62. Kadota K, Nitadori J, Sima CS, et al. Tumor spread through air spaces is an important pattern of invasion and impacts the frequency and location of recurrences after limited resection for small stage I lung adenocar-cinomas. J Thorac Oncol. 2015;10:806-814.
63. Morales-Oyarvide V, Mino-Kenudson M. Tumor islands and spread through air spaces: distinct patterns of invasion in lung adenocarcinoma. Pathol Int. 2016;66:1-7.
64. Nitadori J, Bograd AJ, Kadota K, et al. Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller. J Natl Cancer Inst. 2013;105:1212-1220.
65. Onozato ML, Kovach AE, Yeap BY, et al. Tumor islands in resected early-stage lung adenocarcinomas are associated with unique clinicopathologic and molecular characteristics and worse prognosis. Am J Surg Pathol. 2013;37:287-294.
66. Warth A, Muley T, Kossakowski CA, et al. Prognostic impact of intra-alveolar tumor spread in pulmonary adenocarcinoma. Am J Surg Pathol. 2015;39:793-801.
67. Trejo Bittar HE, Incharoen P, Althouse AD, et al. Accuracy of the IASLC/ATS/ERS histological subtyping of stage I lung adenocarcinoma on intraoperative frozen sections. Mod Pathol. 2015;28:1058-1063.
68. Yeh YC, Kadota K, Nitadori J, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification predicts occult lymph node metastasis in clinically mediastinal node-negative lung adenocarcinoma. Eur J Cardiothorac Surg. 2016;49:e9-e15.
69. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543-550.
70. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489:519-525.
71. Clinical Lung Cancer Genome Project, Network Genomic Medicine. A genomics-based classification of human lung tumors. Sci Transl Med. 2013;5:209ra153.
72. Fernandez-Cuesta L, Peifer M, Lu X, et al. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat Commun. 2014;5:3518.
73. George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524:47-53.
74. Govindan R, Ding L, Griffith M, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012;150:1121-1134.
75. Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012;150:1107-1120.
76. Kim Y, Hammerman PS, Kim J, et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol. 2014;32:121-128.
77. Peifer M, Fernandez-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012;44:1104-1110.
78. Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012;44:1111-1116.
79. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311:1998-2006.
80. Wang R, Zhang Y, Pan Y, et al. Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients. Oncotarget. 2015;6:34300-34308.
81. Shea M, Costa DB, Rangachari D. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis. 2016;10:113-129.
82. Rami-Porta R, Bolejack V, Giroux DJ, et al. The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2014;9:1618-1624.
83. Asamura H, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;10: 1675-1684.
84. Eberhardt WE, Mitchell A, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2015;10:1515-1522.
85. Rami-Porta R, Bolejack V, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;10:990-1003.
86. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39-51.
87. Nicholson AG, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11: 300-311.
88. Rami-Porta R, Wittekind C, Goldstraw P. Complete resection in lung cancer surgery: proposed definition. Lung Cancer. 2005;49:25-33.
89. Asamura H, Hishida T, Suzuki K, et al. Radiographically determined noninvasive adenocarcinoma of the lung: survival outcomes of Japan Clinical Oncology Group 0201. J Thorac Cardiovasc Surg. 2013;146:24-30.
90. Cheng YD, Duan CJ, Dong S, et al. Clinical controlled comparison between lobectomy and segmental resection for patients over 70 years of age with clinical stage I non-small cell lung cancer. Eur J Surg Oncol. 2012;38:1149-1155.
91. Pallis AG, Gridelli C, Wedding U, et al. Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. Ann Oncol. 2014;25:1270-1283.
92. Rivera C, Dahan M, Bernard A, et al. Surgical treatment of lung cancer in the octogenarians: results of a nationwide audit. Eur J Cardiothorac Surg. 2011;39:981-986.
93. Weyant MJ. Treatment of elderly and high risk patients with localized NSCLC [abstract]. J Thorac Oncol. 2015;10(suppl): ED06.03.
94. Zhang R, Ferguson MK. Video-assisted versus open lo-bectomy in patients with compromised lung function: a literature review and meta-analysis. PLoS One. 2015;10:e0124512.
95. El-Sherif A, Gooding WE, Santos R, et al. Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis. Ann Thorac Surg. 2006;82:408-415 [discussion: 415-406].
96. Nakamura K, Saji H, Nakajima R, et al. A phase III randomized trial of lobectomy versus limited resection for small sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L). Jpn J Clin Oncol. 2010;40:271-274.
97. Asamura H. Role of limited sublobar resection for early-stage lung cancer: steady progress. J Clin Oncol. 2014;32:2403-2404.
98. Asamura H. Rationale for sublobar resection for early cancer. J Thorac Oncol. 2015;10:S106.
99. Ashraf H, Dirksen A, Loft A, et al. Combined use of positron emission tomography and volume doubling time in lung cancer screening with low-dose CT scanning. Thorax. 2011;66:315-319.
100. Henschke CI, Yankelevitz DF, Libby DM, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006;355:1763-1771.
101. Pastorino U. Role of PET scan in workup of nodules. J Thorac Oncol. 2015;10:S133.
102. Van Schil PE, Asamura H, Rusch VW, et al. Surgical implications of the new IASLC/ATS/ERS adenocarcinoma classification. Eur Respir J. 2012;39:478-486.
103. Veronesi G. When to intervene on screening detected lung nodules. J Thorac Oncol. 2015;10:S105.
104. Veronesi G, Maisonneuve P, Bellomi M, et al. Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study. Ann Intern Med. 2012;157:776-784.
105. Veronesi G, Maisonneuve P, Pelosi G, et al. Screening-detected lung cancers: is systematic nodal dissection always essential? J Thorac Oncol. 2011;6:525-530.
106. Veronesi G, Maisonneuve P, Spaggiari L, et al. Diagnostic performance of low-dose computed tomography screening for lung cancer over five years. J Thorac Oncol. 2014;9:935-939.
107. Veronesi G, Travaini LL, Maisonneuve P, et al. Positron emission tomography in the diagnostic work-up of screening-detected lung nodules. Eur Respir J. 2015;45:501-510.
108. Yankelevitz DF, Yip R, Smith JP, et al. CT Screening for lung cancer: nonsolid nodules in baseline and annual repeat rounds. Radiology. 2015;277:555-564.
109. Darling GE, Li F, Patsios D, et al. Neoadjuvant chemo-radiation and surgery improves survival outcomes compared with definitive chemoradiation in the treatment of stage IIIA N2 non-small-cell lung cancer. Eur J Cardiothorac Surg. 2015;48:684-690 [discussion: 690].
110. Eberhardt WE. Concurrent chemoradiotherapy in stage III non-small-cell lung cancer: what is the best regimen? J Clin Oncol. 2015;33:532-533.
111. Eberhardt WE, De Ruysscher D, Weder W, et al. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol. 2015;26:1573-1588.
112. Eberhardt WE, Pottgen C, Gauler TC, et al. Phase III study of surgery versus definitive concurrent chemo-radiotherapy boost in patients with resectable stage IIIA (N2) and selected IIIB non-small-cell lung cancer after induction chemotherapy and concurrent chemo-radiotherapy (ESPATUE). J Clin Oncol. 2015;33:4194-4201.
113. Eberhardt WE, Stuschke M. Multimodal treatment of non-small-cell lung cancer. Lancet. 2015;386:1018-1020.
114. McCloskey P, Balduyck B, Van Schil PE, et al. Radical treatment of non-small cell lung cancer during the last 5 years. Eur J Cancer. 2013;49:1555-1564.
115. McElnay PJ, Choong A, Jordan E, et al. Outcome of surgery versus radiotherapy after induction treatment in patients with N2 disease: systematic review and meta-analysis of randomised trials. Thorax. 2015;70:764-768.
116. Pless M, Stupp R, Ris HB, et al. Induction chemo-radiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet. 2015;386:1049-1056.
117. Van Schil PE, Hendriks JM, Hertoghs M, et al. Current surgical treatment of non-small-cell lung cancer. Expert Rev Anticancer Ther. 2011;11:1577-1585.
118. Downey RJ, Ng KK, Kris MG, et al. A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis. Lung Cancer. 2002;38:193-197.
119. Van Schil PE, Hendriks JM, Carp L, et al. Surgery for oligometastatic disease in non-small-cell lung cancer. Expert Rev Anticancer Ther. 2008;8:1931-1938.
120. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351-360.
121. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7:719-727.
122. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552-3559.
123. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589-2597.
124. Wakelee HA, Dahlberg SE, Keller SM, et al. Randomized phase III trial of adjuvant chemotherapy with or without bevacizumab in resected non-small cell lung cancer (NSCLC): results of E1505. J Thorac Oncol. 2015;10:S796.
125. Kelly K, Altorki NK, Eberhardt WE, et al. Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J Clin Oncol. 2015;33: 4007-4014.
126. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355: 983-991.
127. Massuti B, Cobo M, Rodriguez-Paniagua JM, et al. Randomized phase III trial of customized adjuvant chemotherapy (CT) according BRCA-1 expression levels in patients with node positive resected non-small cell lung cancer (NSCLS) SCAT: A Spanish Lung Cancer Group trial (Eudract:2007-000067-15; NCTgov: 00478699) [abstract]. J Clin Oncol. 2015;33(suppl):7507.
128. Wislez M, Barlesi F, Besse B, et al. Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE. J Clin Oncol. 2014;32:1256-1261.
129. Vansteenkiste JF, Cho B, Vanakesa T, et al. 1173OMA-GRIT, a double-blind, randomized, placebo-controlled phase III study to assess the efficacy of the recMAGE-A3 + AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small cell lung cancer (NSCLC). Ann Oncol. 2014;25:iv409.
130. Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer [news release]. London, UK: GlaxoSmithKline; April 2, 2014. https://us.gsk.com/en-us/media/press-releases/2014/update-on-phase-iii-clinical-trial-of-investigational-mage-a3-antigen-specific-cancer-immunotherapeutic-in-non-small-cell-lung-cancer/. Accessed March 10, 2016.
131. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303:1070-1076.
132. Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16:630-637.
133. Hamaji M, Chen F, Matsuo Y, et al. Video-assisted thor-acoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancer. Ann Thorac Surg. 2015;99: 1122-1129.
134. Matsuo Y, Chen F, Hamaji M, et al. Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lo-bectomy: a propensity score matching analysis. Eur J Cancer. 2014;50:2932-2938.
135. Van Schil P. Surgery vs. SBRT in operable NSCLC-surgery. J Thorac Oncol. 2015;10:S169-S170.
136. Bezjak A, Paulus R, Gaspar LE, et al. Primary study endpoint analysis for NRG Oncology/RTOG 0813 trial of stereotactic body radiation therapy (SBRT) for centrally located non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 2016;94:5-6.
137. Bradley JD, Gao F, Parikh PJ, et al. Prospective phase 2 clinical trial of radiation dose-escalated stereotactic body radiation therapy (SBRT) for centrally located lung cancer: an institutional trial. Int J Radiat Oncol Biol Phys. 2015;93:S101.
138. Li T, Kung HJ, Mack PC, et al. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013;31:1039-1049.
139. Seo JS, Ju YS, Lee WC, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 2012;22:2109-2119.
140. Takano T, Fukui T, Ohe Y, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol. 2008;26:5589-5595.
141. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011;12: 1004-1012.
142. Mitsudomi T, Tsai C-M, Shepherd F, et al. AZD9291 in pre-treated T790M positive advanced NSCLC: AURA2 phase II study. J Thorac Oncol. 2015;10:S320.
143. Yang JC-H, Ahn M-J, Ramalingam SS, et al. AZD9291 in pre-treated T790M positive advanced NSCLC: AURA study phase II extension cohort. J Thorac Oncol. 2015;10:S319.
144. Stahel RA. A phase II trial of erlotinib (E) and bev-acizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial. Eur J Cancer. 2015;51:S711.
145. Sequist LV, Goldman JW, Wakelee HA, et al. Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts) [abstract]. J Clin Oncol. 2015;33(suppl):8001.
146. Ali S, Hensing T, Schrock A, et al. Comprehensive genomic profiling identifies a subset of crizotinib responsive ALK-rearranged NSCLC not detected by FISH. Oncologist, in press.
147. Drilon A, Wang L, Arcila ME, et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarci-nomas otherwise negative for such alterations by other genomic testing approaches. Clin Cancer Res. 2015;21:3631-3639.
148. Iyevleva AG, Raskin GA, Tiurin VI, et al. Novel ALK fusion partners in lung cancer. Cancer Lett. 2015;362:116-121.
149. Shan L, Jiang P, Xu F, et al. BIRC6-ALK, a novel fusion gene in ALK break-apart FISH-negative lung adenocar-cinoma, responds to crizotinib. J Thorac Oncol. 2015;10:e37-e39.
150. Hrustanovic G, Olivas V, Pazarentzos E, et al. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015;21: 1038-1047.
151. Crystal AS, Shaw AT, Sequist LV, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science. 2014;346: 1480-1486.
152. US Food and Drug Administration. Ventana ALK (D5F3) CDx assay. June 12, 2015. http://www.fda.gov/medical devices/productsandmedicalprocedures/deviceapprovalsand clearances/recently-approveddevices/ucm454476.htm. Accessed January 22, 2016.
153. Costa DB, Shaw AT, Ou SH, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain me-tastases. J Clin Oncol. 2015;33:1881-1888.
154. Gainor JF, Sherman CA, Willoughby K, et al. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol. 2015;10:232-236.
155. Ou SH, Sommers KR, Azada MC, et al. Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. Oncologist. 2015;20:224-226.
156. Ou SI, Ahn JS, De Petris L, et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol. 2016;34:661-668.
157. Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016;17:234-242.
158. Chiari R, Metro G, Iacono D, et al. Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis. Lung Cancer. 2015;90: 255-260.
159. Gainor JF, Tan DS, De Pas T, et al. Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib. Clin Cancer Res. 2015;21:2745-2752.
160. Shaw AT, Bauer TM, Felip E, et al. Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+ NSCLC [abstract]. J Clin Oncol. 2015;33(suppl):8018.
161. Zou HY, Friboulet L, Kodack DP, et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation alk inhibitors in preclinical models. Cancer Cell. 2015;28:70-81.
162. Zou HY, Li Q, Engstrom LD, et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc Natl Acad Sci USA. 2015;112:3493-3498.
163. Ou SH, Greenbowe J, Khan ZU, et al. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib. Lung Cancer. 2015;88:231-234.
164. Ou SH, Milliken JC, Azada MC, et al. ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression. Lung Cancer. 2016;91:70-72.
165. Kodityal S, Elvin JA, Squillace R, et al. A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib. Lung Cancer. 2016;92:19-21.
166. Toyokawa G, Inamasu E, Shimamatsu S, et al. Identification of a novel ALK G1123S mutation in a patient with ALK-rearranged non-small-cell lung cancer exhibiting resistance to ceritinib. J Thorac Oncol. 2015;10: e55-e57.
167. Shaw AT, Friboulet L, Leshchiner I, et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med. 2016;374:54-61.
168. Ou SH, Chalmers ZR, Azada MC, et al. Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocar-cinoma by comprehensive genomic profiling. Lung Cancer. 2015;88:352-354.
169. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371:1963-1971.
170. Zheng Z, Liebers M, Zhelyazkova B, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med. 2014;20:1479-1484.
171. Zhu Q, Zhan P, Zhang X, et al. Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res. 2015;4:300-309.
172. Pfizer announces U.S. FDA acceptance and priority review of supplemental new drug application for Xalkori (crizo-tinib) for the treatment of patients with ROS1-positive metastatic non-small cell lung cancer [press release]. New York, NY: Pfizer; December 8, 2015. http://press.pfizer.com/press-release/pfizer-announces-us-fda-acceptance-and-priority-review-supplemental-new-drug-applicati. Accessed January 22, 2015.
173. Mazieres J, Zalcman G, Crino L, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol. 2015;33:992-999.
174. FDA expands use of Xalkori to treat rare form of advanced non-small cell lung cancer [press release]. New York, NY: Phfizer; March 11, 2016. http://www. fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm490329.htm. Accessed March 29, 2016.
175. Awad MM, Katayama R, McTigue M, et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med. 2013;368:2395-2401.
176. Song A, Kim TM, Kim DW, et al. Molecular changes associated with acquired resistance to crizotinib in ros1-rearranged non-small cell lung cancer. Clin Cancer Res. 2015;21:2379-2387.
177. Drilon A, Somwar R, Wagner JP, et al. A novel crizotinib-resistant solvent-front mutation responsive to cabo-zantinib therapy in a patient with ROS1-rearranged lung cancer [e-pub ahead of print]. Clin Cancer Res. http://dx.doi.org/10.1158/1078-0432.CCR-15-2013, accessed March 11, 2016.
178. Park K, Tan E-H, Zhang L, et al. Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, phase IIb trial LUX-Lung 7 (LL7). Ann Oncol. 2015;26:ix161-ix162.
179. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240-2247.
180. U.S. Food and Drug Administration. Highlights of prescribing information. TAGRISSO (osimertinib) tablet, for oral use. Initial U.S. approval: 2015. http://www. accessdata.fda.gov/drugsatfda-docs/label/2015/2080 65s000lbl.pdf. Accessed January 22, 2016.
181. Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015;16:763-774.
182. Soria JC, Felip E, Cobo M, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2015;16:897-907.
183. FDA and EMA accept regulatory applications for Boeh-ringer Ingelheim's Giotrif/Gilotrif (afatinib) for treatment of advanced squamous cell carcinoma of the lung [press release]. Ingelheim, Germany: Boehringer Ingel-heim; August 25, 2015. https://www.boehringer-ingelheim.com/news/news-releases/press-releases/2015/25-august-2015-oncology.html. Accessed March 10, 2016.
184. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
185. Kinno T, Tsuta K, Shiraishi K, et al. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations. Ann Oncol. 2014;25:138-142.
186. Litvak AM, Paik PK, Woo KM, et al. Clinical characteristics and course of 63 patients with BRAF mutant lung cancers. J Thorac Oncol. 2014;9:1669-1674.
187. Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29:3574-3579.
188. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011;29:2046-2051.
189. Planchard D, Mazieres J, Riely GJ, et al. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients [abstract]. J Clin Oncol. 2013;31(suppl):8009.
190. Planchard D, Groen HJM, Kim TM, et al. Interim results of a phase II study of the BRAF inhibitor (BRAFi) dab-rafenib (D) in combination with the MEK inhibitor tra-metinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2015;33(suppl):8006.
191. Gautschi O, Pauli C, Strobel K, et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol. 2012;7:e23-e24.
192. Gautschi O, Peters S, Zoete V, et al. Lung adenocarci-noma with BRAF G469L mutation refractory to vemur-afenib. Lung Cancer. 2013;82:365-367.
193. Peters S, Michielin O, Zimmermann S. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol. 2013;31:e341-e344.
194. Robinson SD, O'Shaughnessy JA, Cowey CL, et al. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. Lung Cancer. 2014;85:326-330.
195. Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer. 2001;92:1525-1530.
196. Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res. 2008;14:5731-5734.
197. Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011;22: 2616-2624.
198. Sun Y, Ren Y, Fang Z, et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol. 2010;28:4616-4620.
199. Janne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013;14:38-47.
200. Carter CA, Rajan A, Szabo E, et al. Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations [abstract]. J Clin Oncol. 2013;31(suppl):8026.
201. Blumenschein GR, Smit EF, Planchard D, et al. MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2013;31(suppl):8029.
202. Gandara DR, Hiret S, Blumenschein GR, et al. Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial [abstract]. J Clin Oncol. 2013;31(suppl): 8028.
203. Kelly K, Mazieres J, Leighl NB, et al. Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial [abstract]. J Clin Oncol. 2013;31(suppl):8027.
204. Scagliotti G, von Pawel J, Novello S, et al. Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015;33:2667-2674.
205. Sequist LV, von Pawel J, Garmey EG, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol. 2011;29:3307-3315.
206. Gerber DE, Camidge DR, Morgensztern D, et al. Phase II study of defactinib, VS-6063, a focal adhesion kinase (FAK) inhibitor, in patients with KRAS mutant non-small cell lung cancer (NSCLC). J Thorac Oncol. 2015;10:S372.
207. Skoulidis F, Byers LA, Diao L, et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015;5:860-877.
208. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012;18:375-377.
209. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18:378-381.
210. Wang R, Hu H, Pan Y, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol. 2012;30:4352-4359.
211. Mukhopadhyay S, Pennell NA, Ali SM, et al. RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinib. J Thorac Oncol. 2014;9:1714-1719.
212. Michels S, Scheel AH, Scheffler M, et al. Clinicopatho-logical characteristics of RET rearranged lung cancer in European patients. J Thorac Oncol. 2016;11:122-127.
213. Drilon A, Bergagnin I, Delasos L, et al. Clinical outcomes with pemetrexed-based systemic therapy in RET-rearranged lung cancers. J Thorac Oncol. 2015;10:S178.
214. Drilon A, Wang L, Hasanovic A, et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013;3:630-635.
215. Falchook GS, Ordonez NG, Bastida CC, et al. Effect of the RET inhibitor vandetanib in a patient with RET fusion-positive metastatic non-small-cell lung cancer [e-pub ahead of print]. J Clin Oncol. http://dx.doi.org/10.1200/JCO.2013.50.5016, accessed March 11, 2016.
216. Gautschi O, Zander T, Keller FA, et al. A patient with lung adenocarcinoma and RET fusion treated with van-detanib. J Thorac Oncol. 2013;8:e43-e44.
217. Kodama T, Tsukaguchi T, Satoh Y, et al. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. Mol Cancer Ther. 2014;13: 2910-2918.
218. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18:382-384.
219. Beau-Faller M, Ruppert AM, Voegeli AC, et al. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naive cohort. J Thorac Oncol. 2008;3:331-339.
220. Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol. 2009;27:1667-1674.
221. Ichimura E, Maeshima A, Nakajima T, et al. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res. 1996;87:1063-1069.
222. Moro-Sibilot D, Le Deley M-C, Zalcman G, et al. Activity of crizotinib in METamplified NSCLC: preliminary results of the AcSé trial. J Thorac Oncol. 2015;10:S178.
223. Onozato R, Kosaka T, Kuwano H, et al. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol. 2009;4:5-11.
224. Camidge D, Ou S, Shapiro G, et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol. 2014:32.
225. Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizo-tinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 2011;6: 942-946.
226. Scagliotti G, Novello S, Ramlau R, et al. MARQUEE: A randomized, double-blind, placebo-controlled, phase 3 trial of tivantinib (ARQ 197) plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small-cell lung cancer (NSCLC). Eur J Cancer. 2013;49:S798-S799.
227. Scagliotti GV, Novello S, Schiller JH, et al. Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Clin Lung Cancer. 2012;13: 391-395.
228. Paik PK, Drilon A, Fan PD, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015;5:842-849.
229. Liu X, Jia Y, Stoopler MB, et al. Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations. J Clin Oncol. 2015.
230. Farago AF, Le LP, Zheng Z, et al. Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer. J Thorac Oncol. 2015;10:1670-1674.
231. Vaishnavi A, Capelletti M, Le AT, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013;19:1469-1472.
232. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1-10.
233. Sznol M, Kluger HM, Hodi FS, et al. Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase 1 trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538) [abstract]. J Clin Oncol. 2013;31(suppl):CRA9006.
234. Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squa-mous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16: 257-265.
235. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-135.
236. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-1639.
237. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.
238. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEY-NOTE-010): a randomised controlled trial [e-pub ahead of print]. Lancet. http://dx.doi.org/10.1016/S0140-6736(15)01281-7, accessed March 11, 2016.
239. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizu-mab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multi-centre, open-label, phase 2 randomised controlled trial [e-pub ahead of print]. Lancet, http://dx.doi.org/10. 1016/S0140-6736(16)00587-0, accessed March 29, 2016.
240. Lutzky J, Antonia SJ, Blake-Haskins A, et al. A phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumors [abstract]. J Clin Oncol. 2014;32(suppl):3001.
241. Antonia SJ, Goldberg SB, Balmanoukian AS, et al. Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC [abstract]. J Clin Oncol. 2015;33(suppl):3014.
242. Guibert N, Delaunay M, Mazieres J. Targeting the immune system to treat lung cancer: rationale and clinical experience. Ther Adv Respir Dis. 2015;9:105-120.
243. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375-2391.
244. Kerr KM, Hirsch FR. Programmed death ligand 1 immu-nohistochemistry: friend or foe? Arch Pathol Lab Med. 2016;140:326-331.
245. Kerr KM, Nicolson MC. Non-small cell lung cancer, PD-L1, and the pathologist. Arch Pathol Lab Med. 2016;140:249-254.
246. Kerr KM, Tsao MS, Nicholson AG, et al. Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art? J Thorac Oncol. 2015;10:985-989.
247. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124-128.
248. Redman MW, Allegra CJ. The master protocol concept. Semin Oncol. 2015;42:724-730.
249. Ferrarotto R, Redman MW, Gandara DR, et al. Lung-MAP-framework, overview, and design principles. Chin Clin Oncol. 2015;4:36.
250. Herbst RS, Gandara DR, Hirsch FR, et al. Lung master protocol (Lung-MAP) - A biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin Cancer Res. 2015;21:1514-1524.
251. Levit L, Balogh E, Nass S, et al. Delivering high-quality cancer care: charting a new course for a system in crisis. National Academies Press; 2013. http://iom. nationalacademies.org/Reports/2013/Delivering-High-Quality-Cancer-Care-Charting-a-New-Course-for-a-System-in-Crisis.aspx?utm-sourcefeedburner&utm-medium feed&utm-campaigneed%3A+IomTopicHealthServicesCoverageAndAccess+%28IOM+Topic%3A+Health+Services+ Coverage+and+Access%29. Accessed March 11, 2016.
252. Shih YC, Ganz PA, Aberle D, et al. Delivering high-quality and affordable care throughout the cancer care continuum. J Clin Oncol. 2013;31:4151-4157.
253. Hassett M, Bach P. Toward a comprehensive cancer measure set: value-based episodes of care. Workshop May. 2008;20. https://www.qualityforum. org/Projects/c-d/Cancer-Measure-Set-Value-Based- Episodes-of-Care/Comprehensive-Cancer-Measure- Set--Value-Based-Episodes-of-Care.aspx. Accessed March 11, 2016.
254. Ellis LM, Bernstein DS, Voest EE, et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014;32:1277-1280.
255. Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol. 2015;26: 1547-1573.
256. Schnipper LE, Davidson NE, Wollins DS, et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33:2563-2577.